AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph on page 3, line 13, to page 5, line 7 with the following rewritten paragraph:

A first object of the invention is the use of radio-nuclide labelled conjugates of substance P and a chelator molecule, having the abbreviation Chelator-R-Arg^{1}- Pro^{2}-Lys^{3}-Pro^{4}-Gln^{5}-Gln^{6}-Phe^{7}-Phe^{8}-Gly^{9}-Leu^{10}-Met^{11}-NH_2 and comprising compounds of formula I



(I),

wherein

R is -CH2-C(O)-, -C<u>H</u>(CO_2H)CH_2CH_2-C(O)-or C<u>H</u>(CO_2H)CH_2-C(O)-,

or an analogue of formula I with at least one of the subsequent modifications in the amino acid sequence of substance P:

a) replacement of Met^{11} by -NH-CH(CH_2CH_2-SO_2-CH_3)-C(O)- (<u>hereinafter abbreviated</u> Met(O_2)^{11}), -NH-CH(CH_2CH_2-SO-CH_3)-C(O)- (<u>hereinafter abbreviated</u> Met(O)^{11}), or -NH-CH[CH(CH_3)CH_2CH_3)-C(O)- (<u>hereinafter abbreviated</u> Ile^{11}),

b) replacement of Leu^{10} by -NH-CH[CH(CH_3)CH_2CH_3)-C(O)- (<u>hereinafter abbreviated</u> Ile^{10}),

c) replacement of Gly^{9} by -N(CH_3)-CH_2-C(O)- (<u>hereinafter abbreviated</u> Sar^{9}),

d) replacement of Phe^{7} or Phe^{8} or both Phe^{7} and Phe^{8} by residue of formulae


(2-Thi[7,8]),

(3-BzThi[7,8]),


(2-Nal[7,8]),

(1-Nal[7,8]),


(Phegly[7,8]),

(Cha[7,8]),

e) replacement of Lys^3 by residue of formulae


(Arg[3]), or

(Orn[3]),

f) truncation of 1 to 5 amino acids of the sequence Arg^1- Pro^2-Lys^3-Pro^4-Gln^5, or

g) replacement of 1 to 5 amino acids of the sequence Arg^1- Pro^2-Lys^3-Pro^4-Gln^5 by -$N(CH_3)$-CH_2-C(O)- (hereinafter abbreviated Sar),

and wherein the conjugate is labelled with a radio-nuclide selected from the group consisting of Actinium-225, Bismut-212, Bismut-213, Lead-203, Copper-64, Copper-67,

Gallium-66, Gallium-67, Gallium-68, Lutetium-177, Indium-111, Indium-113, Yttrium-86 and Yttrium-90, Dyprosium-162, Dysprosium-165, Dysprosium-167, Holmium-166, Praseodymium-142, Praseodymium-143, Promethium-149, and Terbium-149, as active ingredient in radio-pharmaceutical or radio-diagnostic formulations for targeting or treating brain tumors, especially gliomas.

Please replace the paragraph on page 5, lines 9-15 with the following rewritten paragraph:

When R in formula I attached to the tetraazamacrocyclic residue is $-CH_2-C(O)-$, it is abbreviated as chelator DOTA; when R in formula I attached to the tetraazamacrocyclic residue is $-C\underline{H}(CO_2H)CH_2CH_2-C(O)-$, it is abbreviated as chelator DOTAGA; and when R in formula I attached to the tetraazacyclic residue is $-C\underline{H}(CO_2H)CH_2-C(O)-$, it is abbreviated as chelator DOTASA. When the carboxylic groups in the chelator moieties are esterified, for example with t-butanol, then the residues are named prochelator. The prochelators can be used for convenient coupling to peptides during solid phase synthesis.

Please replace the paragraph on page 9, line 5 to page 11, line 6 with the following rewritten paragraph:

A further object of the invention are conjugates of substance P or substance P analogues and a chelator molecule, whereby substance P conjugate has the abbreviation Chelator-R-Arg^1- Pro^2-Lys^3-Pro^4-Gln^5-Gln^6-Phe^7-Phe^8-Gly^9-Leu^{10}-Met^{11}-NH_2 and comprises compounds of formula I



(I),

wherein

R is $-CH_2-C(O)-$, $-C\underline{H}(CO_2H)CH_2CH_2-C(O)-$ or $-C\underline{H}(CO_2H)CH_2-C(O)-$, with the proviso that R is

$-CH_2-C(O)-$, when the conjugate comprises the substance P sequence,

and an analogue of formula I with at least one of the subsequent modifications in the amino acid sequence of substance P:

a) replacement of Met^{11} by $-NH-CH(CH_2CH_2-SO_2-CH_3)-C(O)-$ (hereinafter abbreviated $Met(O_2)^{11}$), $-NH-CH(CH_2CH_2-SO-CH_3)-C(O)-$ (hereinafter abbreviated $Met(O)^{11}$), or $-NH-CH[CH(CH_3)CH_2CH_3)-C(O)-$ (hereinafter abbreviated Ile^{11}),

b) replacement of Leu^{10} by $-NH-CH[CH(CH_3)CH_2CH_3)-C(O)-$ (hereinafter abbreviated Ile^{10}),

c) replacement of Gly^9 by $-N(CH_3)-CH_2-C(O)-$ (hereinafter abbreviated Sar^9),

d) replacement of Phe^7 or Phe^8 or both Phe^7 and Phe^8 by residue of formulae



(2-$Thi^{7,8}$),



(3-$BzThi^{7,8}$),


(2-Nal^{7,8}),

(1-Nal^{7,8}),


(Phegly^{7,8}),

(Cha^{7,8}),

e) replacement of Lys^3 by residue of formulae


(Arg^3), or

(Orn^3),

f) truncation of 1 to 5 amino acids of the sequence Arg^1- Pro^2-Lys^3-Pro^4-Gln^5, or

g) replacement of 1 to 5 amino acids of the sequence Arg^1- Pro^2-Lys^3-Pro^4-Gln^5 by -N(CH_3)-CH_2-C(O)- (hereinafter abbreviated Sar),

and wherein the conjugates are unlabelled or labelled with a radionuclide selected from the group consisting of Actinium-225, Bismut-212, Bismut-213, Lead-203, Copper-64, Copper-67, Gallium-66, Gallium-67, Gallium-68, Lutetium-177, Indium-111, Indium-113, Yttrium-86 and Yttrium-90, Dyprosium-162, Dysprosium-165, Dysprosium-167, Holmium-166, Praseodymium-142, Praseodymium-143, Promethium-149, and Terbium-149;

including preferred embodiments of the analogues as mentioned before.

Please replace the paragraph on page 11, line 8 to page 13, line 4 with the following rewritten paragraph:

Still a further object of the invention is a composition comprising (a) at least one pharmaceutical carrier and (b) at least one conjugate of a substance P or an analogue of substance P and a chelator molecule, whereby substance P conjugate has the abbreviation Chelator-R-Arg^{1}- Pro^{2}-Lys^{3}-Pro^{4}-Gln^{5}-Gln^{6}-Phe^{7}-Phe^{8}-Gly^{9}-Leu^{10}-Met^{11}-NH_2 and comprises compounds of formula I



(I),

wherein

R is -CH_2-C(O)-, -C<u>H</u>(CO_2H)CH_2CH_2-C(O)- or -C<u>H</u>(CO_2H)CH_2-C(O)-, with the proviso that R is

-CH_2-C(O)-, when the conjugate comprises the substance P sequence,

and an analogue of formula I with at least one of the subsequent modifications in the amino acid sequence of substance P:

a) replacement of Met^{11} by -NH-CH(CH_2CH_2-SO_2-CH_3)-C(O)- (<u>hereinafter abbreviated</u> Met(O_2)^{11}), -NH-CH(CH_2CH_2-SO-CH_3)-C(O)- (<u>hereinafter abbreviated</u> Met(O)^{11}), or -NH-CH[CH(CH_3)CH_2CH_3)-C(O)- (<u>hereinafter abbreviated</u> Ile^{11}),

b) replacement of Leu^{10} by -NH-CH[CH(CH_3)CH_2CH_3)-C(O)- (<u>hereinafter abbreviated</u> Ile^{10}),

c) replacement of Gly^{9} by -N(CH_3)-CH_2-C(O)- (<u>hereinafter abbreviated</u> Sar^{9}),

d) replacement of Phe^{7} or Phe^{8} or both Phe^{7} and Phe^{8} by residue of formulae


(2-Thi[7,8]),

(3-BzThi[7,8]),


(2-Nal[7,8]),

(1-Nal[7,8]),


(Phegly[7,8]),

(Cha[7,8]),

e) replacement of Lys^3 by residue of formulae


(Arg^3), or

(Orn^3),

f) truncation of 1 to 5 amino acids of the sequence Arg^1- Pro^2-Lys^3-Pro^4-Gln^5, or

g) replacement of 1 to 5 amino acids of the sequence Arg^1- Pro^2-Lys^3-Pro^4-Gln^5 by -$N(CH_3)$-CH_2-C(O)- (hereinafter abbreviated Sar),

and wherein the conjugates are labelled with a radionuclide selected from the group consisting of Actinium-225, Bismut-212, Bismut-213, Lead-203, Copper-64, Copper-67, Gallium-66, Gallium-67, Gallium-68, Lutetium-177, Indium-111, Indium-113, Yttrium-86 and Yttrium-90, Dyprosium-162, Dysprosium-165, Dysprosium-167, Holmium-166, Praseodymium-142, Praseodymium-143, Promethium-149, and Terbium-149;
including preferred embodiments of the analogues as mentioned before.